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HUMAN RESPRATORY SYNCYTIAL VIRUS VACCNE CROSS-REFERENCE TO RELATED APPLICATIONS
This present application claims priority of U.S. Provi sional Patent Application Nos. 61/504,989, filed Jul. 6, 2011, and 61/548,248, filed Oct. 18, 2011, which are specifically incorporated by reference in their entirety.
FIELD OF THE APPLICATION
The present application relates to the field of immunology, in particular, a vaccine composition of the human respiratory syncytial virus (HRSV) strain, L19 (HRSV-L19) that is a hyperproducer of the structural Fusion (F) and Glycoprotein (G) viral proteins, and the use of HRSV-L19 as a vaccine against HRSV infections. The application further relates to the combination of HRSV-L19 with a nanoemulsion, which is a potent immune enhancer, to induce a protective immune response and avoid vaccine-induce disease enhancement.
BACKGROUND OF THE INVENTION
Respiratory Syncytial Virus (RSV) is a leading cause of serious respiratory disease in young children and the elderly worldwide and there is no vaccine available against this pathogen. Human respiratory syncytial virus (HRSV) infec tion commonly results in bronchiolitis and is the leading cause for infant hospitalization in the developed countries. In addition, HRSV is increasingly being described as a major pathogen in the elderly, transplant patients, and chronic obstructive pulmonary disease (COPD) patients (ref 1) . The development of a safe and immunogenic vaccine to address the infant and elderly population presents a unique opportunity.
Previous methods of viral inactivation for vaccine formu lation, Such as formaldehyde, resulted in enhanced pulmo nary disease and mortality. Extensive research into the development of viral vaccines to address HRSV has met with limited Success. Some of the major challenges for HRSV vaccine development include early age of infection, evasion of innate immunity, failure of natural infection to induce immunity that prevent infection, and the demonstra tion of vaccine-enhance illness (ref2).
Approaches have included inactivation of viruses with formalin and the demonstration of vaccine-induced enhancement of diseases when infected with HRSV. The observation that formalin inactivated vaccines have shown disease-enhancement, including showing the skewed immune response that is important to prevent enhancement, and priming by mature dendritic cells, are essential for a protective immune response. Moreover, having F protein in its native state to maintain conformational epitopes is essen tial for the generation of neutralizing antibodies (refs. 3, 4, 5) . The uses of live attenuated vaccines have met with limited Success, as the vaccines have been shown to be minimally immunogenic (ref6). The utilization of a recom binant F protein vaccine showed reduced immunogenicity, with the demonstration that the purified F protein is struc turally immature and not the appropriate version for eliciting neutralizing antibodies (ref 7, 8) . With the use of a subunit vaccine, having an optimal level of F protein is critical for inducing the appropriate immune response, as the subunit vaccines have been hindered by the inefficient and inappro priate expression of F protein (ref 9 2 that a subunit vaccine containing F protein, even with adjuvant, is not completely protective and optimal (ref 11) , Suggests that F protein presentation within its native state in the virion is essential for usage as a vaccine.
The biological challenges and safety concerns of devel opment of a HRSV-L19 present a unique opportunity for a safe and durable vaccine against HRSV.
As with most vaccines, greater immunogenicity is also sought as it correlates with greater efficacy in humans. The prior art has typically disclosed the use of recombinant proteins (e.g., U.S. Pat. Nos. 7,192.595; 6,194.546; 5,962, 298) , as well as the addition of adjuvants such as aluminum (U.S. Pat. No. 6,861,244) and muramyldipeptide (U.S. Pat. No. 4, 826, 687) to compositions to increase the immunoge nicity. However, there still exists a need to develop highly effective RSV vaccines with improved storage stability and ease of administration, which are characteristics of the nanoemulsion vaccines of the present invention.
Prior teachings related to nanoemulsions are described in There remains a need in the art for an effective RSV vaccine and methods of making and using the same. The present invention satisfies these needs.
SUMMARY OF THE INVENTION
The present invention provides a novel approach for inducing a protective immune response against HRSV infec 3 tion by the isolation of a HRSV viral strain which is a hyperproducer of the pivotal immunogenic viral structural proteins, F and G proteins. Having a vaccine candidate that produces higher levels of F protein in its native state within the confines of the normal viral replication cycle is seminal for its usage as an immunogen, as ample amount and proper conformational epitopes will be presented for the generation of neutralizing antibodies and further induction of the pro tective cellular arm of the immune response.
The inventors have succeeded in cultivating HRSV-L19 and demonstrating that the viral strain is a hyperproducer of F and G viral proteins when compared to the commonly used RSV viral strain A2. The more than 2-fold greater levels of the immunogenic F and G protein found within HRSV-L19 is a novel observation which allows for the use of either attenuated or inactivated virus as a vaccine.
The invention encompasses a vaccine composition com prising a purified respiratory syncytial virus (RSV) strain L19 (RSV-L19). In another embodiment, the RSV-L19 virus is a hyperproducer of Fusion (F) and Glycoprotein (G) structural proteins associated with viral particles. In yet another embodiment, the RSV-L19 virus is attenuated human respiratory syncytial virus (HRSV) strain L19. In one embodiment, the vaccine composition comprises a human respiratory syncytial virus deposited with the American Type Culture Collection (ATCC) as HRSV-L19.
In another embodiment of the invention, there is provided a method for preparing an immunogenic preparation, whereby HRSV-L19 is genetically engineered with attenu ating mutations and deletions resulting in an attenuating phenotype. The resulting attenuated virus is cultured in an appropriate cell line and harvested. The harvested virus is then purified free from cellular and serum components. The purified virus is then mixed in an acceptable pharmaceutical carrier for use a vaccine composition. Thus, described are vaccine compositions comprising an RSV viral genome (such as RSV Strain L19) comprising at least one attenuating mutation. In yet another embodiment, the vaccine compo sitions comprise an RSV viral genome (such as RSV strain L19) comprising nucleotide modifications denoting attenu ating phenotypes.
In one embodiment, described is a method for enhancing immunity to human respiratory syncytial virus infections comprising administering to a Subject a nanoemulsion for mulation comprising HRSV-L19. Another embodiment of the invention is directed to a method for inducing an enhanced immunity against disease caused by human respi ratory syncytial virus comprising the step of administering to a subject an effective amount of a purified HRSV-L19 vaccine composition. In some embodiments, the Subject can produce a protective immune response after at least a single administration of the nanoemulsion vaccine. In addition, the immune response can be protective against one or more strains of RSV. The induction of enhanced immunity to HRSV is dependent upon the presence of optimal levels of antigen. Furthermore, the identification of the critical level of antigen is important for providing a robust immune response. The demonstration that F protein levels are directly correlated with the presence and persistence of neutralizing antibodies and protection against viral chal lenge, demonstrates that having a viral Strain that produces optimal levels of the critical immunogenic F protein expressed in its natural orientation is seminal for usage as a vaccine candidate.
In one embodiment of the invention, there is provided a method for preparing an immunogenic preparation, whereby the viral strain HRSV-L19 is cultured in an appropriate cell purified free from cellular and serum components. In a further embodiment of the invention, the purified HRSV L19 is then inactivated and adjuvanted with a nanoemulsion formulation to provide a non-infectious and immunogenic virus. The simple mixing of a nanoemulsion with a vaccine candidate has been shown to produce both mucosal and system immune response. The mixing of the RSV virion particles with a nanoemulsion results in discrete antigen particles in the oil core of the droplet. The antigen is incorporated within the core and this allows it to be in a free form which promotes the normal antigen conformation.
In one embodiment of the invention, the RSV vaccines comprise an adjuvant. In another embodiment, the adjuvant is a nanoemulsion. The nanoemulsion can comprise an aqueous phase, at least one oil, at least one surfactant, and at least one solvent.
In one embodiment of the invention, the present invention provides methods, compositions and kits for inducing an immune response to RSV in a subject. The methods com prise administering to a Subject a nanoemulsion RSV vac cine, wherein the nanoemulsion RSV vaccine comprises droplets having an average diameter of less than about 1000 nm. The nanoemulsion RSV vaccine can further comprise an aqueous phase, at least one oil, at least one surfactant, at least one organic solvent, at least one RSV immunogen, and optionally at least one chelating agent. In another embodi ment, the nanoemulsion RSV vaccine may be administered via any pharmaceutically acceptable method, including but not limited to intranasally. In yet another embodiment of the invention, the nanoemulsion RSV vaccine lacks an organic solvent. Furthermore, additional adjuvants may be added to the nanoemulsion RSV vaccine.
The RSV vaccines may be formulated as a liquid disper Sion, gel, aerosol, pulmonary aerosol, nasal aerosol, oint ment, cream, or solid dose. In addition, the RSV vaccines may be administered via any pharmaceutically acceptable method. Such as parenterally, orally or intranasally. The parenteral administration can be by Subcutaneous, intraperi toneal or intramuscular injection.
In another embodiment of the invention, the nanoemul sion and/or nanoemulsion vaccine is not systemically toxic to the Subject, produces minimal or no inflammation upon administration, or any combination thereof.
In one embodiment of the invention, the subject under goes seroconversion after a single administration of the RSV vaccine.
In yet another embodiment of the invention, the nanoe mulsion RSV vaccine composition comprises (a) at least one cationic Surfactant; (b) a cationic Surfactant which is cetylpyridinium chloride; (c) a cationic Surfactant, and wherein the concentration of the cationic Surfactant is less than about 5.0% and greater than about 0.001%; (d) a cationic Surfactant, and wherein the concentration of the cationic Surfactant is selected from the group consisting of less than about 5%, less than about 4.5%, less than about 4.0%, less than about 3.5%, less than about 3.0%, less than about 2.5%, less than about 2.0%, less than about 1.5%, less than about 1.0%, less than about 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60%, less than about 0.50%, less than about 0.40%, less than about 0.30%, less than about 0.20%, less than about 0.10%, greater than about 0.001%, greater than about 0.002%, greater than about 0.003%, greater than about 0.004%, greater than about 0.005%, greater than about 0.006%, greater than about 5 0.007%, greater than about 0.008%, greater than about 0.009%, and greater than about 0.010%; or (e) any combi nation thereof.
In another embodiment of the invention, the nanoemul sion RSV vaccine composition comprises (a) at least one to about 2%; or (g) any combination thereof.
In yet another embodiment of the invention, the RSV vaccines comprise low molecular weight chitosan, medium molecular weight chitosan, high molecular weight chitosan, a glucan, or any combination thereof. The low molecular weight chitosan, median molecular weight chitosan, high molecular weight chitosan, a glucan, or any combination thereof can be present in the nanoemulsion.
The foregoing general description and following brief description of the drawings and the detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention. WsoPss5EC nanoemulsion mixed with either 1.6x10 PFU RSV strain L19 containing 3.3 ug F protein (n=8) or 3.2x10 PFU RSV strain L19 containing 6.6 ug F protein (n=8). Neutralization units (NEU) represent a reciprocal of the highest dilution that resulted in 50% plaque reduction. NEU measurements were performed at 4 weeks (pre boost) and at 6 weeks (2 weeks post boost). Specimens obtained at 6 weeks generated humoral immune responses adequate to allow for NEU analysis. Data is presented as geometric mean with 95% confidence interval (CI) (FIG. 13A) The present invention provides methods, compositions and kits for the stimulation of an immune response to an RSV immunogen. The present inventors Surprisingly dis covered that cells infected with RSV L19 virus produce between 3-11 fold higher quantities of RSV viral proteins as compared to cells infected with RSV A2 virus (see Example 1, infra.). In one embodiment of the invention, the RSV antigen present in the vaccines of the invention is RSV L19 virus, and more preferably human RSV L19 virus, including the purified, attenuated human respiratory syncytial virus (HRSV) strain L19 (HRSV-L19). In yet other embodiments of the invention, the HSV viral genome can comprise at least one attenuating mutation, including but not limited to nucleotide modifications denoting attenuating phenotypes. Rationale for Selection of RSV L19 Strain: NanoBio developed and optimized RSV propagation and purification methods for three viral strains grown in Vero cells and has established multiplicity of Infection (MOI), optimized puri fication and concentration of the antigen using PEG6000 precipitation and ultracentrifugation. Importantly and uniquely, the RSV L19 viral strain is unique in that it produces significantly higher yields of F protein (approxi mately 10-30 fold more per PFU) than the other strains. F protein content may be a key factor in immunogenicity and the L19 strain currently elicits the most robust immune response. The L19 strain has a shorter propagation time and therefore will be more efficient from a manufacturing per spective. The results comparing the three viral strains are provided in Table 11 and adjuvanted RSV L19 vaccines are highly immunogenic in the universally accepted cotton rat model. Cotton rats elicited a rise in antibody titers after one immunization and a significant boost after the second immunization (approxi mately a 10-fold increase). The antibodies generated are highly effective in neutralizing live virus and there is a linear relationship between neutralization and antibody titers. Fur thermore, antibodies generated in cotton rats showed cross protection when immunized with the RSV L19 strain and challenged with the RSV A2 strain. Both IM and IN immu nization established memory that can be invoked or recalled after an exposure to antigen either as a second boost or exposure to live virus. The methods comprise administering to a subject a nanoe mulsion RSV vaccine, wherein the nanoemulsion vaccine comprises droplets having an average diameter of less than about 1000 nm. The nanoemulsion RSV vaccine further comprises (a) an aqueous phase, (b) at least one oil, (c) at least one surfactant, (d) at least one organic solvent, (e) at least one RSV antigen, and (f) optionally comprising at least one chelating agent, or any combination thereof. In another embodiment of the invention, the nanoemulsion lacks an organic solvent. In one embodiment, the subject is selected from adults, elderly Subjects, juvenile Subjects, infants, high risk Sub jects, pregnant women, and immunocompromised subjects.
In another embodiment, the nanoemulsion RSV vaccine may be administered intranasally.
The nanoemulsion compositions of the invention function as a vaccine adjuvant. Adjuvants serve to: (1) bring the antigen-the Substance that stimulates the specific protec tive immune response-into contact with the immune sys tem and influence the type of immunity produced, as well as the quality of the immune response (magnitude or duration); (2) decrease the toxicity of certain antigens; (3) reduce the amount of antigen needed for a protective response; (4) reduce the number of doses required for protection; (5) enhance immunity in poorly responding Subsets of the population and/or (7) provide solubility to some vaccines components. The nanoemulsion vaccine adjuvants are par ticularly useful for adjuvanting RSV vaccines.
In one embodiment of the invention, the RSV vaccines comprise F protein of an RSV strain, such as but not limited to F protein of RSV strain L19. In another embodiment, the RSV vaccines comprise about 0.1 ug up to about 100 g, and any amount in-between, of RSVF protein, such as F protein of RSV strain L19. For example, the RSV vaccines can comprise about 0.1 ug, about 0. 10, 7.5x10, 8.0x10, 8.5x10, 9.0x10, 9.5x10, 10x10, 1.5x10, 2.0x10, 2.5x10, 3.0x10, 3.5x10, 40x10, 4.5x 10°, 5.0x10°, 5.5x10, 6.0x10, 6.5x10°, 7.0x10°, 7.5x10, 8.0x10, 8.5x10, 9.0x10, 9.5x10, 10x107, 1.5x107, 2.0x 10, 2.5x107, 3.0x107, 3.5x107, 40x107, 4.5x107, 5.0x107, 5.5x107, 6.0x107, 6.5x107, 7.0x107, 7.5x107, 8.0x107, 8.5x 107.9.0x107.9.5x10", 1.0x10 pful of an RSV virus, such as RSV Strain L19.
In another embodiment of the invention, the RSV vac cines of the invention comprising RSV strain L19 are cross-reactive against at least one other RSV Strain (or cross-reactive against one or more RSV Strains). As it is known to one of ordinary skill in the art, cross reactivity can be measured 1) using ELISA method to see if the sera from vaccinated animals or individuals will produce antibodies against Strains that were not used in the administered vac cine; 2) Immune cells will produce cytokines when stimu lated in vitro using stains that were not used in the admin istered vaccine. Cross protection can be measured in vitro when antibodies in Sera of animals vaccinated with one strain will neutralize infectivity of another virus not used in the administered vaccine.
For example, the RSV vaccines of the invention compris ing RSV Strain L19 can be cross reactive against one or more RSV strains selected from the group consisting of RSV strain A2 (wild type) (ATCC VR (2008)). These studies demonstrate the broad application of the nanoemulsion adjuvant with a variety of antigens includ ing RSV antigens.
The nanoemulsion RSV vaccine of the invention can be administered to a Subject using any pharmaceutically accept able method, such as for example, intranasal, buccal, Sub lingual, oral, rectal, ocular, parenteral (intravenously, intra dermally, intramuscularly, Subcutaneously, intracisternally, intraperitoneally), pulmonary, intravaginal, locally adminis tered, topically administered, topically administered after scarification, mucosally administered, via an aerosol, or via a buccal or nasal spray formulation. Further, the nanoemul sion RSV vaccine can be formulated into any pharmaceu tically acceptable dosage form, Such as a liquid dispersion, gel, aerosol, pulmonary aerosol, nasal aerosol, ointment, cream, semi-solid dosage form, or a suspension. Further, the nanoemulsion RSV vaccine may be a controlled release formulation, Sustained release formulation, immediate release formulation, or any combination thereof. Further, the nanoemulsion RSV vaccine may be a transdermal delivery system Such as a patch or administered by a pressurized or pneumatic device (i.e., a 'gene gun).
In one embodiment of the invention, the nanoemulsion RSV vaccine comprises droplets having an average diameter of less than about 1000 nm and: (a) an aqueous phase; (b) about 1% oil to about 80% oil; (c) about 0.1% to about 50% organic solvent; (d) about 0.001% to about 10% of a Surfactant or detergent; or (e) any combination thereof. In another embodiment of the invention, the nanoemulsion vaccine comprises: (a) an aqueous phase; (b) about 1% oil to about 80% oil; (c) about 0.1% to about 50% organic solvent; (d) about 0.001% to about 10% of a surfactant or detergent; and (e) at least one RSV immunogen. In another embodiment of the invention, the nanoemulsion lacks an organic solvent.
The quantities of each component present in the nanoe mulsion and/or nanoemulsion vaccine refer to a therapeutic nanoemulsion and/or nanoemulsion RSV vaccine.
In one embodiment, the nanoemulsion vaccine droplets have an average diameter selected from the group consisting of less than about 1000 nm, less than about 950 nm, less than about 900 nm, less than about 850 nm, less than about 800 nm, less than about 750 nm, less than about 700 nm, less than about 650 nm, less than about 600 nm, less than about 550 nm, less than about 500 nm, less than about 450 nm, less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, greater than about 50 nm, greater than about 70 nm, greater than about 125 nm, and any combination thereof.
In one embodiment, the nanoemulsion and/or nanoemul sion vaccine comprises a cationic Surfactant which is cetylpyridinium chloride (CPC). CPC may have a concen tration in the nanoemulsion RSV vaccine of less than about 5.0% and greater than about 0.001%, or further, may have a concentration of less than about 5%, less than about 4.5%, less than about 4.0%, less than about 3.5%, less than about 3.0%, less than about 2.5%, less than about 2.0%, less than about 1.5%, less than about 1.0%, less than about 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60%, less than about 0.50%, less than about 0.40%, less than about 0.30%, less than about 0.20%, less than about 0.10%, greater than about 0.001%, greater than about 0.002%, greater than about 0.003%, greater than about 0.004%, greater than about 0.005%, greater than about 0.006%, greater than about 0.007%, greater than about 0.008%, greater than about 0.009%, and greater than about O.O10%.
In a further embodiment, the nanoemulsion RSV vaccine comprises a non-ionic Surfactant, Such as a polysorbate surfactant, which may be polysorbate 80 or polysorbate 20, and may have a concentration of about 0.01% to about 5.0%, or about 0.1% to about 3% of polysorbate 80. The nanoe mulsion RSV vaccine may further comprise at least one preservative. In another embodiment of the invention, the nanoemulsion RSV vaccine comprises a chelating agent.
In yet another embodiment, the nanoemulsion RSV vac cine further comprises an immune modulator, such as chi tosan or glucan. An immune modulator can be present in the vaccine composition at any pharmaceutically acceptable amount including, but not limited to, from about 0.001% up to about 10%, and any amount in between, Such as about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 13 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
A. DEFINITIONS As used herein, "about will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, "about will mean up to plus or minus 10% of the particular term.
As used herein, the term "adjuvant" refers to an agent that increases the immune response to an antigen (e.g., a patho gen). As used herein, the term "immune response' refers to a subjects (e.g., a human or another animal) response by the immune system to immunogens (i.e., antigens) which the Subjects immune system recognizes as foreign. Immune responses include both cell-mediated immune responses (responses mediated by antigen-specific T cells and non specific cells of the immune system) and humoral immune responses (responses mediated by antibodies present in the plasma lymph, and tissue fluids). The term "immune response' encompasses both the initial responses to an immunogen (e.g., a pathogen) as well as memory responses that are a result of "acquired immunity."
As used herein, the term "attenuated HRSV refers to viral particles with reduced virulence and pathogenicity and in animal models and human will not result in clinical diseases.
The terms "chelator or "chelating agent" refer to any materials having more than one atom with a lone pair of electrons that are available to bond to a metal ion.
As used herein, the term "enhanced immunity" refers to an increase in the level of acquired immunity to a given pathogen following administration of a vaccine of the pres ent invention relative to the level of acquired immunity when a vaccine of the present invention has not been administered.
As used herein, the term "hyperproducer refers to a viral strain that is capable of selectively producing at least 2-fold higher levels of viral structural proteins over standard viral strains. In the preferred embodiment, hyperproducer refers to the unique demonstration that HRSV-L19 produces levels of F and G proteins that are considerably higher than the comparable A2 HRSV strain.
As used herein, the term "immunogen' refers to an antigen that is capable of eliciting an immune response in a Subject. In preferred embodiments, immunogens elicit immunity against the immunogen (e.g., a pathogen or a pathogen product) when administered in combination with a nanoemulsion of the present invention.
As used herein, the term "inactivated HRSV refers to virion particles that are incapable of infecting host cells and are noninfectious in pertinent animal models.
As used herein, the term "intranasal(ly) refers to appli cation of the compositions of the present invention to the Surface of the skin and mucosal cells and tissues of the nasal passages, e.g., nasal mucosa, sinus cavity, nasal turbinates, or other tissues and cells which line the nasal passages.
The term "nanoemulsion," as used herein, includes small oil-in-water dispersions or droplets, as well as other lipid structures which can form as a result of hydrophobic forces which drive apolar residues (i.e., long hydrocarbon chains) away from water and drive polar head groups toward water, when a water immiscible oily phase is mixed with an aqueous phase. These other lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar 14 lipid vesicles, micelles, and lamellar phases. The present invention contemplates that one skilled in the art will appreciate this distinction when necessary for understanding the specific embodiments herein disclosed.
The terms "pharmaceutically acceptable' or "pharmaco logically acceptable," as used herein, refer to compositions that do not substantially produce adverse allergic or adverse immunological reactions when administered to a host (e.g., an animal or a human). Such formulations include any pharmaceutically acceptable dosage form. Examples of Such pharmaceutically acceptable dosage forms include, but are not limited to, dips, sprays, seed dressings, stem injections, lyophilized dosage forms, sprays, and mists. As used herein, "pharmaceutically acceptable carrier includes any and all Solvents, dispersion media, coatings, Wetting agents (e.g., Sodium lauryl Sulfate), isotonic and absorption delaying agents, disintegrants (e.g., potato starch or Sodium starch glycolate), and the like.
As used herein, the term "topical(ly) refers to application of the compositions of the present invention to the surface of the skin and mucosal cells and tissues (e.g., buccal, lingual, Sublingual, masticatory, respiratory or nasal mucosa, nasal turbinates and other tissues and cells which line hollow organs or body cavities).
As used herein, "viral particles' refers to mature virions, partial virions, empty capsids, defective interfering particles, and viral envelopes.
B. STABILITY OF THE NANOEMULSION RSV VACCINES OF THE INVENTION
The nanoemulsion RSV vaccines of the invention can be stable at about 40° C. and about 75% relative humidity for a time period of at least up to about 2 days, at least up to about 2 weeks, at least up to about 1 month, at least up to about 3 months, at least up to about 6 months, at least up to about 12 months, at least up to about 18 months, at least up to about 2 years, at least up to about 2.5 years, or at least up to about 3 years.
In another embodiment of the invention, the nanoemul sion RSV vaccines of the invention can be stable at about 25° C. and about 60% relative humidity for a time period of at least up least up to about 2 days, at least up to about 2 weeks, to about 1 month, at least up to about 3 months, at least up to about 6 months, at least up to about 12 months, at least up to about 18 months, at least up to about 2 years, at least up to about 2.5 years, or at least up to about 3 years, at least up to about 3.5 years, at least up to about 4 years, at least up to about 4.5 years, or at least up to about 5 years.
Further, the nanoemulsion RSV vaccines of the invention can be stable at about 4°C. for a time period of at least up to about 1 month, at least up to about 3 months, at least up to about 6 months, at least up to about 12 months, at least up to about 18 months, at least up to about 2 years, at least up to about 2.5 years, at least up to about 3 years, at least up to about 3.5 years, at least up to about 4 years, at least up to about 4.5 years, at least up to about 5 years, at least up to about 5.5 years, at least up to about 6 years, at least up to about 6.5 years, or at least up to about 7 years.
The nanoemulsion RSV vaccines of the invention can be stable at about -20° C. for a time period of at least up to about 1 month, at least up to about 3 months, at least up to about 6 months, at least up to about 12 months, at least up to about 18 months, at least up to about 2 years, at least up to about 2.5 years, at least up to about 3 years, at least up to about 3.5 years, at least up to about 4 years, at least up to about 4.5 years, at least up to about 5 years, at least up to about 5.5 years, at least up to about 6 years, at least up to about 6.5 years, or at least up to about 7 years.
These stability parameters are also applicable to nanoe mulsion adjuvants and/or nanoemulsion RSV vaccines.
C. IMMUNE RESPONSE
The immune response of the Subject can be measured by determining the titer and/or presence of antibodies against the RSV immunogen after administration of the nanoemul sion RSV vaccine to evaluate the humoral response to the immunogen. Seroconversion refers to the development of specific antibodies to an immunogen and may be used to evaluate the presence of a protective immune response. Such antibody-based detection is often measured using Western blotting or enzyme-linked immunosorbent (ELISA) assays or hemagglutination inhibition assays (HAI). Persons of skill in the art would readily select and use appropriate detection methods.
Another method for determining the subject's immune response is to determine the cellular immune response. Such as through immunogen-specific cell responses. Such as cyto toxic T lymphocytes, or immunogen-specific lymphocyte proliferation assay. Additionally, challenge by the pathogen may be used to determine the immune response, either in the Subject, or, more likely, in an animal model. A person of skill in the art would be well versed in the methods of determin ing the immune response of a subject and the invention is not limited to any particular method.
D. NANOEMULSION RSV VACCINES
Droplet Size
The nanoemulsion RSV vaccine of the present invention comprises droplets having an average diameter size of less than about 1,000 nm, less than about 950 nm, less than about 900 nm, less than about 850 nm, less than about 800 nm, less than about 750 nm, less than about 700 nm, less than about 650 nm, less than about 600 nm, less than about 550 nm, less than about 500 nm, less than about 450 nm, less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, or any combination thereof. In one embodiment, the droplets have an average diameter size greater than about 125 nm and less than or equal to about 600 nm. In a different embodiment, the droplets have an average diameter size greater than about 50 nm or greater than about 70 nm, and less than or equal to about 125 nm.
Aqueous Phase
The aqueous phase can comprise any type of aqueous phase including, but not limited to, water (e.g., H2O, dis tilled water, purified water, water for injection, de-ionized water, tap water) and Solutions (e.g., phosphate buffered saline (PBS) solution). In certain embodiments, the aqueous phase comprises water at a pH of about 4 to 10, preferably about 6 to 8. The water can be deionized (hereinafter "DiHO). In some embodiments the aqueous phase com prises phosphate buffered saline (PBS). The aqueous phase may further be sterile and pyrogen free.
Organic Solvents
Organic solvents in the nanoemulsion RSV vaccines of the invention include, but are not limited to, C-C alcohol, The volatile oil can be the organic solvent, or the volatile oil can be present in addition to an organic solvent. Suitable volatile oils include, but are not limited to, a terpene, monoterpene, sesquiterpene, carminative, aZulene, menthol, camphor, thujone, thymol, nerol, linalool, limonene, geran iol, perillyl alcohol, nerolidol, farnesol, ylangene, bisabolol. farmesene, ascaridole, chenopodium oil, citronellal, citral, citronellol, chamaZulene, yarrow, guaiaZulene, chamomile, semi-synthetic derivatives, or combinations thereof.
In one aspect of the invention, the volatile oil in the silicone component is different than the oil in the oil phase.
Surfactants
The Surface active agents or surfactants, are amphipathic molecules that consist of a non-polar hydrophobic portion, usually a straight or branched hydrocarbon or fluorocarbon chain containing 8-18 carbon atoms, attached to a polar or ionic hydrophilic portion. The hydrophilic portion can be nonionic, ionic or Zwitterionic. The hydrocarbon chain inter acts weakly with the water molecules in an aqueous envi ronment, whereas the polar or ionic head group interacts strongly with water molecules via dipole or ion-dipole interactions. Based on the nature of the hydrophilic group, Additional suitable surfactants include, but are not limited to, non-ionic lipids, such as glyceryl laurate, glyceryl myristate, glyceryl dilaurate, glyceryl dimyristate, semi synthetic derivatives thereof, and mixtures thereof.
In additional embodiments, the Surfactant is a polyoxy ethylene fatty ether having a polyoxyethylene head group ranging from about 2 to about 100 groups, or an alkoxylated alcohol having the structure Rs (OCH2CH2), OH, wherein Rs is a branched or unbranched alkyl group having from about 6 to about 22 carbon atoms and y is between about 4 and about 100, and preferably, between about 10 and about 100. Preferably, the alkoxylated alcohol is the species wherein Rs is a lauryl group and y has an average value of 23. In a different embodiment, the surfactant is an alkoxylated alcohol which is an ethoxylated derivative of lanolin alco hol. Preferably, the ethoxylated derivative of lanolin alcohol is laneth-10, which is the polyethylene glycol ether of lanolin alcohol with an average ethoxylation value of 10. In addition, the nonionic Surfactant can be a poloxamer. Poloxamers are polymers made of a block of polyoxyeth ylene, followed by a block of polyoxypropylene, followed by a block of polyoxyethylene. The average number of units of polyoxyethylene and polyoxypropylene varies based on the number associated with the polymer. For example, the smallest polymer, Poloxamer 101, consists of a block with an average of 2 units of polyoxyethylene, a block with an average of 16 units of polyoxypropylene, followed by a block with an average of 2 units of polyoxyethylene. Polox amers range from colorless liquids and pastes to white Solids. In cosmetics and personal care products, Poloxamers are used in the formulation of skin cleansers, bath products, benzyl-1-(2-hydroxethyl)-2-imidazolinium chloride, Alkyl bis(2-hydroxyethyl)benzyl ammonium chloride, Alkyl dem ethyl benzyl ammonium chloride, Alkyl dimethyl 3,4-di chlorobenzyl ammonium chloride (100% C), Alkyl dim ethyl 3,4-dichlorobenzyl ammonium chloride (50% C, 40% C, 10% CI), Alkyl dimethyl 3,4-dichlorobenzyl ammonium chloride (55% C, 23% C, 20% C), Alkyl dimethylbenzyl ammonium chloride, Alkyl dimethylbenzyl ammonium chloride (100% C), Alkyl dimethyl benzyl ammonium chloride (100% C), Alkyl dimethyl benzyl ammonium chloride (41% C, 28% C), Alkyl dimethyl benzyl ammonium chloride (47% C, 18% C), Alkyl dimethylbenzyl ammonium chloride (55% C16, 20% C), Alkyl dimethylbenzyl ammonium chloride (58% C, 28% C), Alkyl dimethylbenzyl ammonium chloride (60% Ca 25% CI), Alkyl dimethylbenzyl ammonium chloride (61% C, 23% C), Alkyl dimethylbenzyl ammonium chloride (61% C, 23% Ca), Alkyl dimethyl benzyl ammonium chloride (65% C, 25% CI), Alkyl dimethylbenzyl ammo nium chloride (67% C, 24% C), Alkyl dimethylbenzyl ammonium chloride (67% C, 25% CI), Alkyl dimethyl benzyl ammonium chloride (90% C, 5% CI), Alkyl dimethyl benzyl ammonium chloride (93% C, 4% C), Alkyl dimethyl benzyl ammonium chloride (95% C, 5% Cs), Alkyl dimethyl benzyl ammonium chloride, Alkyl didecyl dimethyl ammonium chloride, Alkyl dimethylben Zyl ammonium chloride, Alkyl dimethylbenzyl ammonium chloride (C), Alkyl dimethyl benzyl ammonium chlo ride (Cs), Alkyl dimethyl benzyl ammonium chloride, dialkyl dimethyl benzyl ammonium chloride, Alkyl dim ethyl dimethylbenzyl ammonium chloride, Alkyl dimethyl ethyl ammonium bromide (90% C, 5% C, 5% CI), 21 Alkyl dimethyl ethyl ammonium bromide (mixed alkyl and alkenyl groups as in the fatty acids of Soybean oil), Alkyl dimethyl ethylbenzyl ammonium chloride, Alkyl dimethyl ethylbenzyl ammonium chloride (60% C), Alkyl dimethyl isopropylbenzyl ammonium chloride (50% C, 30% Ca 17% C, 3% Cs), Alkyl trimethyl ammonium chloride (58% Cs, 40% C, 1% C, 1% CI), Alkyl trimethyl ammonium chloride (90% Cs, 10% CI), Alkyldimethyl (ethylbenzyl)ammonium chloride (Cs), Di-(Cso)-alkyl dimethyl ammonium chlorides, Dialkyl dimethyl ammo nium chloride, Dialkyl methylbenzyl ammonium chloride, Didecyl dimethyl ammonium chloride, Diisodecyl dimethyl ammonium chloride, Dioctyl dimethyl ammonium chloride, Dodecyl bis(2-hydroxyethyl)octyl hydrogen ammonium chloride, Dodecyl dimethyl benzyl ammonium chloride, Dodecylcarbamoyl methyl dimethyl benzyl ammonium chloride, Heptadecyl hydroxyethylimidazolinium chloride, Exemplary cationic halogen-containing compounds include, but are not limited to, cetylpyridinium halides, cetyltrimethylammonium halides, cetyldimethylethylammo nium halides, cetyldimethylbenzylammonium halides, cetyltributylphosphonium halides, dodecyltrimethylammo nium halides, or tetradecyltrimethylammonium halides. In Some particular embodiments, suitable cationic halogen containing compounds comprise, but are not limited to, cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride, cetylbenzyldimethylammonium chloride, cetylpyridinium bromide (CPB), cetyltrimethylammonium bromide (CTAB), cetylidimethylethylammonium bromide, cetyltributylphosphonium bromide, dodecyltrimethylammo nium bromide, and tetradecyltrimethylammonium bromide. In particularly preferred embodiments, the cationic halogen containing compound is CPC, although the compositions of the present invention are not limited to formulation with an particular cationic containing compound. In some embodiments, the nanoemulsion RSV vaccine comprises a cationic surfactant, which can be cetylpyri dinium chloride. In other embodiments of the invention, the nanoemulsion RSV vaccine comprises a cationic Surfactant, and the concentration of the cationic Surfactant is less than about 5.0% and greater than about 0.001%. In yet another embodiment of the invention, the nanoemulsion RSV vac cine comprises a cationic Surfactant, and the concentration of the cationic Surfactant is selected from the group con sisting of less than about 5%, less than about 4.5%, less than about 4.0%, less than about 3.5%, less than about 3.0%, less than about 2.5%, less than about 2.0%, less than about 1.5%, less than about 1.0%, less than about 0.90%, less than about 0.80%, less than about 0.70%, less than about 0.60%, less than about 0.50%, less than about 0.40%, less than about 0.30%, less than about 0.20%, or less than about 0.10%.
Further, the concentration of the cationic agent in the nanoe mulsion vaccine is greater than about 0.002%, greater than about 0.003%, greater than about 0.004%, greater than about 0.005%, greater than about 0.006%, greater than about 0.007%, greater than about 0.008%, greater than about 0.009%, greater than about 0.010%, or greater than about 0.001%. In one embodiment, the concentration of the cat ionic agent in the nanoemulsion vaccine is less than about 5.0% and greater than about 0.001%. limited to one or more solvents, such as an organic phos phate-based solvent, bulking agents, coloring agents, phar maceutically acceptable excipients, a preservative, pH adjuster, buffer, chelating agent, etc. The additional com pounds can be admixed into a previously emulsified nanoe mulsion vaccine, or the additional compounds can be added to the original mixture to be emulsified. In certain of these embodiments, one or more additional compounds are admixed into an existing nanoemulsion composition imme diately prior to its use.
Suitable preservatives in the nanoemulsion RSV vaccines of the invention include, but are not limited to, cetylpyri dinium chloride, benzalkonium chloride, benzyl alcohol, chlorhexidine, imidazolidinyl urea, phenol, potassium Sor bate, benzoic acid, bronopol, chlorocresol, paraben esters, phenoxyethanol, Sorbic acid, alpha-tocophernol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, buty lated hydroxytoluene, sodium ascorbate, Sodium metabisul phite, citric acid, edetic acid, semi-synthetic derivatives thereof, and combinations thereof. Other suitable preserva tives include, but are not limited to, benzyl alcohol, chlo rhexidine (bis(p-chlorophenyldiguanido) hexane), chlorphe nesin (3-(-4-chlorophenoxy)-propane-1,2-diol), Kathon CG (methyl and methylchloroisothiazolinone), parabens (methyl, ethyl, propyl, butyl hydrobenzoates), phenoxyetha nol (2-phenoxyethanol), Sorbic acid (potassium Sorbate, Sorbic acid), Phenonip (phenoxyethanol, methyl, ethyl, butyl, propyl parabens), Phenoroc (phenoxyethanol 0.73%, methyl paraben 0.2%, propyl paraben 0.07%), Liquipar Oil (isopropyl, isobutyl, butylparabens), Liquipar PE (70% phe noxyethanol, 30% liquipar oil), Nipaguard MPA (benzyl alcohol (70%), methyl & propyl parabens), Nipaguard MPS (propylene glycol, methyl & propyl parabens), Nipasept (methyl, ethyl and propyl parabens), Nipastat (methyl, butyl, ethyl and propyel parabens), Elestab 388 (phenoxyethanol in propylene glycol plus chlorphenesin and methylparaben), and Killitol (7.5% chlorphenesin and 7.5% methyl para bens).
The nanoemulsion RSV vaccine may further comprise at least one pH adjuster. Suitable pH adjusters in the nanoe mulsion vaccine of the invention include, but are not limited to, diethyanolamine, lactic acid, monoethanolamine, trieth ylanolamine, Sodium hydroxide, Sodium phosphate, semi synthetic derivatives thereof, and combinations thereof.
In addition, the nanoemulsion RSV vaccine can comprise a chelating agent. In one embodiment of the invention, the chelating agent is present in an amount of about 0.0005% to about 1%. Examples of chelating agents include, but are not limited to, ethylenediamine, ethylenediaminetetraacetic acid (EDTA), phytic acid, polyphosphoric acid, citric acid, glu conic acid, acetic acid, lactic acid, and dimercaprol, and a preferred chelating agent is ethylenediaminetetraacetic acid.
The nanoemulsion RSV vaccine can comprise a buffering agent, Such as a pharmaceutically acceptable buffering agent. Examples of buffering agents include, but are not limited to, 2-Amino-2-methyl-1,3-propanediol, -99.5% (NT), 2-Amino-2-methyl-1-propanol, -99.0% (GC), L-(+)-Tartaric acid, 99.5% (T), ACES, 99.5% (T), ADA, 99.0% (T), Acetic acid, 99.5% (GCIT), Acetic acid, for luminescence, -99.5% (GC/T), Ammonium acetate solu tion, for molecular biology, ~5 M in H2O, Ammonium acetate, for luminescence, 299.0% (calc. on dry substance, T), Ammonium bicarbonate, a 99.5% (T), Ammonium cit The nanoemulsion RSV vaccine can comprise one or more emulsifying agents to aid in the formation of emul sions. Emulsifying agents include compounds that aggregate at the oil/water interface to form a kind of continuous membrane that prevents direct contact between two adjacent droplets. Certain embodiments of the present invention feature nanoemulsion vaccines that may readily be diluted with water or another aqueous phase to a desired concen tration without impairing their desired properties.
Immune Modulators
As noted above, the RSV vaccine can further comprise one or more immune modulators. Examples of immune modulators include, but are not limited to, chitosan, glucan, enterotoxin, nucleic acid (CpG motifs), MF59, alum, ASO system, etc. It is within the purview of one of ordinary skill in the art to employ Suitable immune modulators in the context of the present invention.
An immune modulator can be present in the vaccine composition at any pharmaceutically acceptable amount including, but not limited to, from about 0.001% up to about 10%, and any amount inbetween, such as about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
E. PHARMACEUTICAL COMPOSITIONS
The nanoemulsion RSV vaccines of the invention may be formulated into pharmaceutical compositions that comprise the nanoemulsion RSV vaccine in a therapeutically effective amount and Suitable, pharmaceutically-acceptable excipi ents for pharmaceutically acceptable delivery. Such excipi ents are well known in the art.
By the phrase "therapeutically effective amount' it is meant any amount of the nanoemulsion RSV vaccine that is effective in preventing, treating or ameliorating a disease caused by the RSV pathogen associated with the immuno gen administered in the composition comprising the nanoe mulsion RSV vaccine. By "protective immune response it is meant that the immune response is associated with pre vention, treating, or amelioration of a disease. Complete prevention is not required, though is encompassed by the present invention. The immune response can be evaluated using the methods discussed herein or by any method known by a person of skill in the art.
Intranasal administration includes administration via the nose, either with or without concomitant inhalation during administration. Such administration is typically through contact by the composition comprising the nanoemulsion RSV vaccine with the nasal mucosa, nasal turbinates or sinus cavity. Administration by inhalation comprises intra nasal administration, or may include oral inhalation. Such administration may also include contact with the oral mucosa, bronchial mucosa, and other epithelia.
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Exemplary dosage forms for pharmaceutical administra tion are described herein. Examples include but are not limited to liquids, ointments, creams, emulsions, lotions, gels, bioadhesive gels, sprays, aerosols, pastes, foams, Sun Screens, capsules, microcapsules, Suspensions, pessary, powder, semi-solid dosage form, etc.
The pharmaceutical nanoemulsion RSV vaccines may be formulated for immediate release, Sustained release, con trolled release, delayed release, or any combinations thereof, into the epidermis or dermis. In some embodiments, the formulations may comprise a penetration-enhancing agent. Suitable penetration-enhancing agents include, but are not limited to, alcohols such as ethanol, triglycerides and aloe compositions. The amount of the penetration-enhancing agent may comprise from about 0.5% to about 40% by weight of the formulation.
The nanoemulsion RSV vaccines of the invention can be applied and/or delivered utilizing electrophoretic delivery/ electrophoresis. Further, the composition may be a transder mal delivery system Such as a patch or administered by a pressurized or pneumatic device (i.e., "gene gun). Such methods, which comprise applying an electrical current, are well known in the art.
The pharmaceutical nanoemulsion RSV vaccines for administration may be applied in a single administration or in multiple administrations.
If applied topically, the nanoemulsion RSV vaccines may be occluded or semi-occluded. Occlusion or semi-occlusion may be performed by overlaying a bandage, polyoleofin film, article of clothing, impermeable barrier, or semi impermeable barrier to the topical preparation. An exemplary nanoemulsion adjuvant composition according to the invention is designated "Wso,5EC' adju vant. The composition of Wso,5EC adjuvant is shown in the table below (Table 1 ).H. The mean droplet size for the Wo5EC adjuvant is ~400 nm. All of the components of the nanoemulsion are included on the FDA inactive ingredient list for Approved Drug Products. The nanoemulsion adjuvants are formed by emulsification of an oil, purified water, nonionic detergent, organic solvent and Surfactant, Such as a cationic Surfactant. An exemplary specific nanoemulsion adjuvant is designated as "60% Wo5EC. The 60% W5EC-adjuvant is composed of the ingredients shown in Table 2 below: purified water, USP; soybean oil USP; Dehydrated Alcohol, USP anhydrous ethanol; Polysorbate 80, NF and cetylpyridinium chloride, USP (CPC). All components of this exemplary nanoemul sion are included on the FDA list of approved inactive ingredients for Approved Drug Products. The nanoemulsions of the invention can be formed using classic emulsion forming techniques. See e.g., U.S. 2004/ 0043041. In an exemplary method, the oil is mixed with the aqueous phase under relatively high shear forces (e.g., using high hydraulic and mechanical forces) to obtain a nanoe mulsion comprising oil droplets having an average diameter of less than about 1000 nm. Some embodiments of the invention employ a nanoemulsion having an oil phase comprising an alcohol Such as ethanol. The oil and aqueous phases can be blended using any apparatus capable of producing shear forces Sufficient to form an emulsion, Such as French Presses or high shear mixers (e.g., FDA approved high shear mixers are available, for example, from Admix, Inc., Manchester, N.H.). Methods of producing such emul sions are described in U.S. Pat. Nos. 5,103,497 and 4,895, 452, herein incorporated by reference in their entireties.
In an exemplary embodiment, the nanoemulsions used in the methods of the invention comprise droplets of an oily discontinuous phase dispersed in an aqueous continuous phase, such as water or PBS. The nanoemulsions of the invention are stable, and do not deteriorate even after long storage periods. Certain nanoemulsions of the invention are non-toxic and safe when Swallowed, inhaled, or contacted to the skin of a Subject.
The compositions of the invention can be produced in large quantities and are stable for many months at a broad range of temperatures. The nanoemulsion can have textures ranging from that of a semi-solid cream to that of a thin lotion, to that of a liquid and can be applied topically by any pharmaceutically acceptable method as stated above, e.g., by hand, or nasal dropS/spray.
As stated above, at least a portion of the emulsion may be in the form of lipid structures including, but not limited to, unilamellar, multilamellar, and paucliamellar lipid vesicles, micelles, and lamellar phases.
The present invention contemplates that many variations of the described nanoemulsions will be useful in the meth ods of the present invention. To determine if a candidate nanoemulsion is suitable for use with the present invention, three criteria are analyzed. Using the methods and standards described herein, candidate emulsions can be easily tested to determine if they are suitable. First, the desired ingredients are prepared using the methods described herein, to deter mine if a nanoemulsion can be formed. If a nanoemulsion cannot be formed, the candidate is rejected. Second, the candidate nanoemulsion should form a stable emulsion. A nanoemulsion is stable if it remains in emulsion form for a sufficient period to allow its intended use. For example, for nanoemulsions that are to be stored, shipped, etc., it may be desired that the nanoemulsion remain in emulsion form for months to years. Typical nanoemulsions that are relatively unstable, will lose their form within a day. Third, the candidate nanoemulsion should have efficacy for its intended use. For example, the emulsions of the invention should kill or disable RSV virus to a detectable level, or induce a protective immune response to a detectable level. The nanoemulsion of the invention can be provided in many different types of containers and delivery systems. For example, in Some embodiments of the invention, the nanoe mulsions are provided in a cream or other Solid or semi-solid form. The nanoemulsions of the invention may be incorpo rated into hydrogel formulations.
The nanoemulsions can be delivered (e.g., to a Subject or customers) in any suitable container. Suitable containers can be used that provide one or more single use or multi-use dosages of the nanoemulsion for the desired application. In Some embodiments of the invention, the nanoemulsions are provided in a Suspension or liquid form. Such nanoemul sions can be delivered in any Suitable container including spray bottles and any Suitable pressurized spray device. Such spray bottles may be suitable for delivering the nanoe mulsions intranasally or via inhalation.
These nanoemulsion-containing containers can further be packaged with instructions for use to form kits.
The invention is further described by reference to the following examples, which are provided for illustration only. The invention is not limited to the examples, but rather includes all variations that are evident from the teachings provided herein. All publicly available documents refer enced herein, including but not limited to U.S. patents, are specifically incorporated by reference.
EXAMPLES Example 1
The purpose of this example is to compare HRSV Protein Expression for RSV A2 strain as compared to RSV L19 strain, and Cell Lysate vs. Supernatant.
Materials and Methods: All samples were prepared by infecting HEP-2 cells with the same amount of pfu from either A2 or L19 viruses. Twenty four hours post infection; the infected cells were treated with either one of the fol lowing:
(1) Cell lysate to check for the cell associated proteins: after discarding the Supernatant media, the cells were treated with SDS. This cell lysate was assayed for quantity of F protein associated with the cells. (2) Total cell and Supernatant proteins; the cells and supernatant were frozen and thawed 3 times to lyse the cells and all the cell lysate was used to assay the F protein in the cells and the media. L19 and A2 virus was extracted and purified from HEP-2 infected cells 4 days following infection. Purified virus was compared for protein contents.
Results: Normalized samples were assayed in Western blots using a polyclonal anti RSV antibodies. F and G protein contents were compared between L.19 and A2 strains. The density of the bands was compared using image capturing and a Kodak Software. A mock non-infected cell culture was prepared as a control. Virus. Table 3 shows comparable HRSV F and G protein from L19 and A2 levels from SDS-PAGE. Table 4 shows comparable HRSV L19 and A2 F and G protein from Table 5 shows comparable HRSV L19 and A2 F and G protein from SDS PAGE. 24 hours after virus infection, the first set of Hep-2 cells were lysed with or without culture supernatant. Samples were prepared as the following: Four days after infection, the second set of Hep-2 cells were lysed with or without culture supernatant. Samples were prepared as the following: Table  8 below shows a density analysis of HRSV F and G protein band from Western Blot. In addition, both cell-associated viral particles and culture media-associated viral particles express much higher G in L19 infected cells compared to those infected with RSV A2 strain.
Example 3
The purpose of this example was to demonstrate the associated of a nanoemulsion with viral antigen.
Materials and Methods: Transmission Electron Micro graphs and Sectioning Technique Twenty mL of the nanoe mulsion adjuvant alone or with FluZone(R) was fixed with 1% (w/v) osmium tetroxide solution. The fixed preparations were mixed with histogel in 1:10 ratio to form a solid mass.
The solid mixture of was sliced into thin 1 mm slices and rinsed with double distilled deionizer water. The cross sectioned samples were dehydrated with ascending concen trations (30%, 50%, 70%, 90%, 100%) of component A of the Durcupan(R) kit (Fluka, EM #14020) in double distilled deionizer water. These samples were transferred into embed ding solution (mixture of components A, B, C and D) of the Durcupan R) kit. The embedded samples were sectioned to a 75 nm thickness and placed on 300 mesh carbon-coated copper grid. The sections on the grids were stained with saturated uranyl acetate in distilled and deionizer water (pH 7) for 10 minutes followed by lead citrate for 5 minutes. The samples were viewed with a Philips CM-100 TEM equipped with a computer controlled compuStage, a high resolution (2Kx2K) digital camera and digitally imaged and captured using X-Stream imaging software (SEM Tech Solutions, Inc., North Billerica, Mass.).
Results: Electron Micrographs: Cross sectioned TEM of 20% W5EC nanoemulsion showed nanoemulsion droplets with a uniform inner core material. Nanoemulsion vaccine containing 30 Jug of HA shows discrete antigen materials/ particles inside the oil core of the droplets that represent the FluZone(R) antigens. Since the antigen is incorporated in the core, and is surrounded by the core material, it is protected from staining by the electron dense stain. This leads to a white counter staining effect in the core. The localization of media-associated viral particles express much higher F 65 the antigen within the core shields the antigen-sensitive (about 6 fold average) in L19 infected cells as compared to those infected with RSV A2 strain.
protein subunits in the emulsion, and may protect the antigen from degradation, and thus enhancing stability. There are very few FluZoneR particles outside of the NE particles that were stained dark in color (FIGS. 6a and 6b).
Example 4
The purpose of this example was to compare several different approaches for inactivation of RSV, including B-propiolactone and Wso,5EC Nanoemulsion, via nasal vac cination in a mouse.
Methods: W5EC, an oil-in-water nanoemulsion with both antiviral and adjuvant activity, was compared with B-propiolactone (B-PL) inactivated virus (strain L19 (a)2x105 pfu/dose). The two vaccines were adminis tered intranasally (IN) to BALB/C mice at weeks 0 and 4. Mice were bled prior to dosing and at 3 weeks post-boost and then tested for specific antibodies against F-protein.
Animals were challenged nasally with 1x10 pfu RSV L19 at week 8 and checked for airway hyper-reactivity (AHR), lung cytokines, and viral protein mRNA clearance using PCR.
Results: Both W5EC and B-PL completely inactivated RSV and induced an immune response. B-PL vaccine induced higher antibody response compared to nanoemul sion-inactivated vaccine (p=0.006). Animals vaccinated with nanoemulsion-inactivated vaccine, however, had higher clearance of the RSV following the challenge, evi denced by lower proteins F and G mRNA in the lungs (p=0.06 and 0.0004, respectively). Moreover, animals receiving nanoemulsion-inactivated vaccine demonstrated a significant lower AHR (p=0.02). Both vaccines induced significant levels of lung IL-17 as compared to nonvacci nated control (<0.01), however, significantly higher levels were induced by nanoemulsion-inactivated vaccine (p=0.009).
Conclusions: B-PL inactivated RSV virus vaccine is asso ciated with AHR following viral challenge in a mouse model of RSV infection. In contrast, nanoemulsion viral inactiva tion produced no AHR and induced a significantly increased IL-17 production and improved viral clearance. This Sug gests a novel pathway of immune protection that may provide benefit for vaccination against RSV.
Example 5
The purpose of this example is to describe exemplary nanoemulsions useful as adjuvants for an RSV vaccine.
A total of 10 nanoemulsion formulations were evaluated in mice and cotton rats. W5EC alone, six Wo5EC+ Poloxamer 407 and Poloxamer 188 (P407 and P188) for mulations as well as two Wo5EC+Chitosan and one W5EC+Glucan formulation have been produced and assessed for stability over 2 weeks under accelerated con ditions at 40°C. (Table 1 ). All 10 nanoemulsions were stable for at least 2 weeks at 40° C. The following formulations were specifically tested in cotton rat IN studies: (1) Formulation 1, W5EC (NE80), comprising: (a) CPC/Tween 80 (ratio of 1:6), and (b) Par ticle size ~500 nm (Table 10) Table 11 ). Rationale for Selection of RSV L19 Strain: Nano Bio developed and optimized RSV propagation and purification methods for three viral strains grown in Vero cells and has established multiplicity of Infection (MOI), optimized puri fication and concentration of the antigen using PEG6000 precipitation and ultracentrifugation. Importantly and uniquely, the RSV L19 viral strain is unique in that it produces significantly higher yields of F protein (approxi mately 10-30 fold more per PFU) than the other strains. F protein content may be a key factor in immunogenicity and the L19 strain currently elicits the most robust immune response. The L19 strain has a shorter propagation time and therefore will be more efficient from a manufacturing per spective. NanoBio proposes to produce RSV L19 strain virus for the vaccine in a qualified Vero cell line following single plaque isolation of the L19 strain and purification of the virus to establish a Master Viral Seed Bank and Working Viral Seed Bank. The results comparing the three viral strains are provided in Table 12 . 'kistant temperature-sensitive A2 mutant virus obtained from the NIH (Whitehead 1998).
Example 7
The purpose of this example is to describe Inactivation of RSV L19 viral strain with different nanoemulsion adjuvants.
The nanoemulsions (1) W5EC, (2) W5EC with P407: (3) Ws5EC with P188, (4) W5EC with high and low Inactivation with 20% nanoemulsion was performed for 2 hours at room temperature and with 0.25% PL for 16 hours at 4°C. followed by 2 hours at 37° C. The treated virus was passaged three times in Hep-2 cells and Western blot analy sis was performed on cell lysate to determine presence of live virus. See FIG. 7. In particular, FIG. 7 
Example 8
The purpose of this example was to evaluate the short term stability of RSV vaccines.
Target doses of RSV L19 viral preparations were formu lated to achieve a final nanoemulsion concentration of 20%.
Vaccine was stored at RT and at 4° C. Stability test param eters included physical and chemical analysis (Table 13 ). Physical appearance, mean particle size, Zeta potential and Western Blot acceptance criteria with RSV strain L19 were met following 14 days of storage (longest tested) at RT and 4°C. with W5EC+/-BPL inactivation. W5EC+3% P407, W5EC+0.3% Chitosan-LMW, and W5EC+0.3% Chitosan-MMW were tested for a maximum of 7-8 days and also demonstrated stability. The W5EC/P188 (1:1:5) and W5EC/P188 (1.5:1) formulations were also tested with a live virus RSV A2 strain as opposed to RSV L19 strain for a maximum of 14 days; the 1:1:5 formulation demonstrated stability whereas the 1:5:1 formulation demonstrated poten tial agglomeration (Table 14) . (FIG. 8B) .
Example 9
The purpose of this example was to evaluate the immu nogenicity of an RSV vaccine in mice.
Mice were immunized intramuscularly as shown in Table  15 . Mice received 50 ul of RSV adjuvanted vaccine IM at 0 weeks. Mice were bled on 0 and 3 weeks and tested for serum antibodies. Chitosan was used as an immune-modu lator to enhance the immune response in addition to the adjuvant activity contributed to the nanoemulsion. Mice vaccinated with nanoemulsion containing chitosan showed more enhanced immune response following a single dose of nanoemulsion adjuvanted RSV vaccine when com pared to nanoemulsion without chitosan (FIG. 9) . In par ticular, FIG. 9 shows the immune response (IgG, Ig/ml) at week 3 following vaccination in mice vaccinated IM with in FIG.9 show the highest levels of IgG were found in mice vaccinated with RSV strain L19+2.5% W5EC+ 0.1% Low Mol. Wt. Chitosan, with the next highest levels of IgG found in mice vaccinated with RSV strain L19+2.5% Wo5EC, followed by mice vaccinated with RSV strain L19+5% W5EC. The lowest levels of IgG observed in vaccinated mice were for RSV strain L19+f3PL inactivated virus.
Example 10
The purpose of this example was to determine the immu nogenicity of RSV vaccines according to the invention in Cotton rats.
Cotton rats are the accepted animal species for evaluating immunogenicity and efficacy of RSV vaccines. Using data generated in mice, two nanoemulsions were selected for evaluation in Cotton rats. The two initial formulations studied include the Wso,5EC and the WP'ss5EC (1:1:5) (see Tables 10 and 11 above) .
Cotton rats received two doses of 30 ul IN of the nanoe mulsion-adjuvanted vaccine containing 6.6 ug F-ptn. They were challenged with 5x10 pfu RSV strain A2 at week 23.
Half of the animals were sacrificed at day 4 and half were sacrificed on day 8. The vaccination schedule is demon Immunogenicity data presented below show that upon IN immunization with an RSV-nanoemulsion vaccine, a posi tive immune response was observed. Upon the administra tion of the second dose, a rapid and significant increase in antibody titers were achieved. Data presented in FIG. 11 show that at week 21, the antibody level in all animals was about one tenth of the maximal values obtained shortly after the administration of the first boost at week 4. Administra tion of a second boost prior to the challenge yielded an immune response that was almost identical to levels achieved at week 6, two weeks after the first boost. Both nanoemulsions were equally efficient in eliciting a strong and significant immune responses (FIGS. 11 and 12). (The Y axis in FIGS. 11 and 12 shows the end point titers or antibody quantity of specific antibody to F protein and the X axis shows the time period in weeks.) ELISA Unit/ug/ml: The amount of specific antibody to F protein was calcu lated by area under the curve in the ELISA in relation to a defined reference serum which was assigned an arbitrary 100 EU.
Example 11
The purpose of this example was to determine the effect of RSV vaccines according to the invention on neutralizing antibodies, as well as cross-reactivity of an RSV vaccine comprising RSV strain L19 against other RSV strains fol lowing IN administration.
Cotton rats were vaccinated with 30 ul of vaccine intra nasally, boosted at 4 weeks, and bled at 0, 4, 6, and 8 weeks.
Animals were challenged at week 23 with 5x10 pfu of RSV strain A2. Study groups included two groups that received 20% W5EC nanoemulsion mixed with either 1.6x10 PFU RSV strain L19 containing 3.3 ug F protein (n=8) or 3.2x10 PFU RSV strain L19 containing 6.6 ug F protein (n=8), as well as two groups that received 20% WPss5EC nanoe mulsion mixed with either 1.6x10 PFU RSV strain L19 containing 3.3 g F protein (n=8) or 3.2x10 PFUL19 RSV containing 6.6 ug F protein (n=8).
Half of the animals were sacrificed at Day 4 and half at Day 8. Individual cotton rats sera was tested for neutralizing antibodies. Neutralization units (NEU) represent a recipro cal of the highest dilution that resulted in 50% plaque reduction. NEU measurements were performed at 4 weeks (pre boost) and at 6 weeks (2 weeks post boost). Specimens obtained at 6 weeks generated humoral immune responses adequate to allow for NEU analysis. Data is presented as geometric mean with 95% confidence interval (CI) (FIG.  13A) . Correlation between EU and NEU is for all animals at 6 weeks using Spearman rho (FIG. 13B) .
Specifically, FIG. 13 shows neutralizing antibody titers at 6 weeks time point (FIG. 13A) . It is noteworthy that all animals vaccinated with 3.2x10 PFU RSV strain L19 inac tivated with 60% W5EC or 60% WP1885EC generated robust neutralizing antibodies. There is a statistically sig nificant positive correlation between EU and neutralizing antibodies (NEU) (FIG. 13B) .
Neutralization Unit (NU):
The reciprocal of the highest serum dilution that reduces viral plaques by 50%.
Specific Activity (NU/EU): Viral neutralizing antibody antibodies (NU) per the one EU F-protein antibody (FIG. 13B) FIG. 14 shows neutralizing antibodies on day 4 and day 8. (FIG. 15) .
Serum of vaccinated cotton rats showed cross protection against RSV strain A2 (in addition to RSV strain L19) on Day 4 post-challenge (FIG. 16) The efficacy of IM immunization was assessed by chal lenging the animals with a live A2 strain of RSV, which is a strain that causes disease in humans. A dose of 5x10 pfu of RSV strain A2 was administered to animals two weeks after booster immunization of the RSV L19 nanoemulsion adjuvanted vaccine. A naive age-matched group was also challenged. Half of the animals in each group were sacri ficed on day 4 post challenge, at which time the maximum 41 viral load was demonstrated in the lungs of Cotton Rats. The other half were sacrificed at day 8.
Viral clearance: Lung culture showed that all vaccinated animals had no virus in their lungs at 4 days post challenge while naive animals had virus loads of 10 pfu RSV strain A2/g of lung tissue (FIG. 21). Specifically, FIG. 21 shows viral clearance at Day 4 in the lungs of the cotton rats, by measurement of the RSV strain A2 viral titer (PFU/g) in the lungs of the tested cotton rats. Vaccinated cotton rats (vac cinated with W5EC nanoemulsion combined with RSV strain L19), showed complete clearance of RSV strain A2 challenged virus from the lungs of the cotton rats. In contrast, naive animals showed viral loads of 10 pfu RSV strain A2/gram of lung or greater (limit of detection was 2.1x10" pfu/g).
Cotton Rat Summary: All RSV vaccines formulated in nanoemulsion and administered IN or IM elicited a protec tive immune response that prevented infection of immunized animals. Moreover, nanoemulsion-inactivated and adju vanted RSV L19 vaccines are highly immunogenic in the universally accepted cotton rat model. Cotton rats elicited a rise in antibody titers after one immunization and a signifi cant boost after the second immunization (approximately a 10-fold increase). The antibodies generated are highly effec tive in neutralizing live virus and there is a linear relation ship between neutralization and antibody titers. Further more, antibodies generated in cotton rats showed cross protection when immunized with the RSV L19 strain and challenged with the RSV A2 strain. Both IM and IN immu nization established memory that can be invoked or recalled after an exposure to antigen either as a second boost or exposure to live virus.
Example 13
The purpose of this example was to compare intranasal (IN) versus intramuscular (IM) administration of a Wso,5EC nanoemulsion adjuvanted RSV vaccine.
Methods: RSV vaccine containing 2x10 plaque forming units (PFU) of L19 RSV virus with 1.7 ug of F protein was inactivated with 20% Wso,5EC nanoemulsion adjuvant. BALB/C mice (n=10/arm) were vaccinated at weeks 0 and 4 IN or IM. Serum was analyzed for anti-F antibodies (FIG.  22) . Cells from spleens, cervical and intestinal lymph nodes (LN) were analyzed for RSV-specific cytokines (FIG. 23) .
Mice were challenged oropharyngeally with 5x1OPFUL19 at 8 weeks. Airway hyperreactivity was assessed by plethys mography. Lungs were analyzed day 8 post challenge to assess mRNA of cytokines, viral proteins, and histopathol Ogy.
Results: Mice vaccinated IM had higher anti-F antibodies (GM 396 (95% CI-240-652 vs. 2 95% CI 0-91) (FIG. 22) and generated more IL-4 and IL-13, after challenge (p<0.05) compared to mice vaccinated IN (FIG. 23) . In contrast, IL-17 from spleen cells, cervical LN and intestinal LN was higher after IN vs IM vaccination (GM: 57 vs 1, 119 vs 3 and 51 vs. 4 g/mL, respectively, p<0.05) (FIG. 23). FIG. 24 shows measurement of the cytokines IL-4, IL-13, and IL-17 in lung tissue following either IN or IM vaccination. IL-4 and IL-13 were expressed at higher amounts following IM administration, with IL-17 showing greater expression fol lowing IN administration. Upon challenge, both routes of immunization resulted in clearance of F and G proteins, but airway resistance was higher in the IM group (p=0.03) with confirmatory histopathology (FIG. 25) . Pulmonary IL-4 and IL-13 had a strong positive correlation (r-0.89; p=0.001 and r=0.8; p=0.007, respectively) with airway hyperreactivity. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and varia tions of this invention provided they come within the scope of the appended claims and their equivalents.
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